TL;DR – Quick Answer
CDS22-formula is the continuation of the original De Simone Formulation used for years in VSL#3 and later in Vivomixx 450. The product now sold as Vivomixx Neo in Ireland features a new 9-strain blend that has not been studied in clinical trials. If you are looking for the formulation supported by the established scientific evidence, the option available in Ireland is CDS22-formula.
Introduction
Across Ireland, many people searching for “Vivomixx”, “Vivomixx 450”, or “high-strength probiotics” may not realise that the formulation has changed. This guide has been prepared for Irish readers to explain the current differences between CDS22-formula, which maintains the original De Simone Formulation, and Vivomixx Neo, which is a newly assembled 9-strain probiotic blend.
CDS22-formula is the same 8-strain, 450 billion CFU formulation that featured in the published clinical evidence for the original De Simone Formulation. It was previously commercialised under other brand names, including Vivomixx* (owned by Mendes SA) and VSL#3* (owned by Actial Srl). These brands are no longer connected to the formulation.
What Is CDS22-formula?
- Made with the original De Simone Formulation
- 8 precisely balanced strains
- 450 billion CFU per sachet
- The formulation used in the historical clinical trials
- Matches the composition previously found in VSL#3 (original) and Vivomixx 450
What Is Vivomixx Neo?
Based on publicly available product listings, Vivomixx Neo includes:
- 9 probiotic strains (new “Neo 9” blend)
- Approximately 460 billion CFU per sachet
- Revised strain selection such as IMC 501, IMC 502, SP1 and others
- No clinical studies published on this new formulation
- Does not contain the original De Simone Formulation
CDS22-formula vs Vivomixx Neo – High-Level Comparison
| Feature | CDS22-formula | Vivomixx Neo |
|---|---|---|
| Formulation | Original De Simone Formulation (8 strains) | New Neo blend (9 strains) |
| Clinical Evidence | Supported by historic clinical research | No published trials on Neo 9 |
| CFU per Sachet | 450 billion CFU | ~460 billion CFU |
| Strain Profile | Eight documented strains used in evidence | Nine revised strains with different ratios |
| Positioning | Continuation of the original scientifically tested formulation | New alternative within the Vivomixx range |
Strain-by-Strain Formulation Comparison
The Vivomixx Neo formula does not match the clinically supported De Simone Formulation used in earlier products. CDS22-formula contains the exact same 8 strains referenced in published research, whereas Vivomixx Neo uses a new 9-strain recipe with no clinical trials behind it.
The table below shows each strain, how it appears in CDS22-formula, and how it appears in Vivomixx Neo.
| Strain | CDS22-formula (Original De Simone Formulation) | Vivomixx Neo 9 (per sachet) |
|---|---|---|
| Streptococcus thermophilus |
Present S. thermophilus DSM 24731 / NCIMB 30438 Included in 450 billion CFU |
Present S. thermophilus SP4 – 9 billion CFU |
| Bifidobacterium breve |
Present B. breve DSM 24732 / NCIMB 30441 Included in 450 billion CFU |
Present B. breve Br8 – 9 billion CFU |
| Bifidobacterium longum |
Present B. longum DSM 24736 / NCIMB 30442 Included in 450 billion CFU |
Not present |
| Bifidobacterium infantis |
Present B. infantis DSM 24737 / NCIMB 30443 Included in 450 billion CFU |
Not present |
| Lactobacillus acidophilus |
Present L. acidophilus DSM 24735 / NCIMB 30439 Included in 450 billion CFU |
Present L. acidophilus LA1 – 9 billion CFU |
| Lactobacillus plantarum |
Present L. plantarum DSM 24730 / NCIMB 30437 Included in 450 billion CFU |
Present L. plantarum SP1 – 26 billion CFU L. plantarum 14D – 9 billion CFU |
| Lactobacillus paracasei |
Present L. paracasei DSM 24733 / NCIMB 30445 Included in 450 billion CFU |
Present L. paracasei IMC 502 – 190 billion CFU |
| Lactobacillus delbrueckii subsp. bulgaricus |
Present L. delbrueckii DSM 24734 / NCIMB 30440 Included in 450 billion CFU |
Not present |
| Lactococcus lactis | Not present |
Present L. lactis SP38 – 9 billion CFU |
| Bifidobacterium animalis subsp. lactis | Not present |
Present B. animalis BL1 – 9 billion CFU |
What Customers Say About CDS22-formula
Irish customers consistently highlight three things:
- Reliable continuity with the original De Simone Formulation.
- Fast delivery from within Ireland.
- Clear, transparent information about the formulation and its origins.
You can read verified customer experiences on our Trustpilot page:
View live Trustpilot reviews for CDS22-formula
Clinical Evidence Overview
The original De Simone Formulation is supported by more than 200 publications. All of these studies relate to the 8-strain formulation now found in CDS22-formula. Vivomixx Neo does not use this formulation, and there are currently no peer-reviewed clinical trials on the Neo 9 blend.
Irish Advisory Context
In Ireland, CDS22-formula and similar products are classified as food supplements, not medicines. They are intended to complement a varied and balanced diet, not to diagnose, treat, or cure any disease. Probiotic.ie prepares product information in line with Irish guidance for food supplements and labelling. Anyone with underlying health conditions, or who is pregnant, breastfeeding, or taking prescription medicines, should discuss probiotic use with a GP, pharmacist, or other registered healthcare professional.
Are They Interchangeable?
No. The strain identities and ratios differ substantially. Evidence for the De Simone Formulation cannot be applied to the Neo blend, as they are not the same product.
When People in Ireland Choose CDS22-formula
- They previously used VSL#3 (original) or Vivomixx 450 and want continuity
- They prefer a formulation with a long track record in the scientific literature
- They want clarity on exactly which strains are included and how they compare
- They value fast delivery from within Ireland rather than cross-border shipping
- They prefer to buy from an Irish-owned specialist retailer with local support
When People Choose Vivomixx Neo
- Familiarity with the Vivomixx brand name
- A preference for a 9-strain blend
- Convenience of availability through certain Irish pharmacies or retailers
Summary
- The original Vivomixx 450 used the De Simone Formulation.
- Vivomixx Neo is a different recipe with nine strains.
- Only CDS22-formula contains the original 8-strain formulation.
- The Neo blend has no published clinical trials.
- For evidence continuity, CDS22-formula is the direct match to the original formulation.
Where to Buy CDS22-formula in Ireland
CDS22-formula is supplied by Probiotic.ie, an Irish-owned retailer based in Dublin, with fast delivery throughout Ireland:
https://probiotic.ie/collections/cds22-formula
Why Irish Customers Choose Probiotic.ie
- Irish-owned business with a focus on gut health
- Orders shipped from within Ireland, avoiding customs delays
- Transparent information about formulations and strain differences
- Customer service based in Ireland
- Access to CDS22-formula, containing the original De Simone Formulation
Frequently Asked Questions
Is the original Vivomixx still available in Ireland?
No. The original Vivomixx 450 is no longer supplied. The version now available is Vivomixx Neo, which uses a different formulation.
Is Vivomixx Neo the same as Vivomixx 450?
No. Vivomixx Neo contains a revised 9-strain blend and does not use the original De Simone Formulation.
Which product contains the original De Simone Formulation?
CDS22-formula contains the original 8-strain formulation used in the historical clinical research.
Can people switch from Vivomixx Neo to CDS22-formula?
These formulations are different. Many people who previously used Vivomixx 450 choose CDS22-formula to stay with the formulation they recognise.
Does Vivomixx Neo have published clinical evidence?
No clinical trials have been published on the Neo 9 blend. Published evidence relates to the original De Simone Formulation.
About the Author and Editorial Review
About the author: This guide was prepared for Irish readers by the editorial team at Probiotic.ie, an Irish-owned specialist retailer supplying high-strength probiotics nationwide. The team has extensive experience working with evidence-based gut health formulations, including the original De Simone Formulation. See About Us for more informaion/
Editorial approach: All articles on Probiotic.ie are based on publicly available scientific literature and product information. Content is written for a general Irish audience and is designed to support, not replace, advice from registered healthcare professionals in Ireland.
Scientific References and Sources
The following sources include independent regulatory guidance, public science databases, and a curated list of clinical studies validating the original De Simone Formulation — useful for readers based in Ireland.
- European Food Safety Authority (EFSA) – Qualified Presumption of Safety (QPS) list
- Food Safety Authority of Ireland (FSAI) – Food Supplements Guidance
- National Institutes of Health (NIH) – Probiotics: What You Need to Know
- National Library of Medicine / PubMed – Peer-Reviewed Probiotic Research Database
- 80+ Clinical Studies – Bibliography for the Original De Simone Formulation
- 200+ Scientific Papers – Publications Relating to the Original Formulation
Author: Probiotic.ie Editorial Team
Reviewed by: CDS22-formula Scientific Advisory Notes (Non-medical)
Further Scientific Reading
The studies below are examples of peer-reviewed clinical research conducted on the original De Simone Formulation. They are provided for readers who wish to explore the scientific literature in more detail.
-
Ulcerative colitis – induction of remission
Sood A, et al. “VSL#3 probiotic mixture induces remission in patients with active ulcerative colitis.” Clin Gastroenterol Hepatol. 2009.
https://pubmed.ncbi.nlm.nih.gov/19327479/ -
Pouchitis – prevention of relapse
Gionchetti P, et al. “Prophylaxis of pouchitis onset with probiotic therapy containing VSL#3.” Gastroenterology. 2003.
https://pubmed.ncbi.nlm.nih.gov/12891538/ -
IBS – symptom improvement
Kim HJ, et al. “A probiotic combination (VSL#3) improves IBS symptoms.” Am J Gastroenterol. 2003.
https://pubmed.ncbi.nlm.nih.gov/14572571/ -
Inflammatory bowel disease – safety and tolerance
Bibiloni R, et al. “The effects of VSL#3 in patients with inflammatory bowel disease.” Inflamm Bowel Dis. 2005.
https://pubmed.ncbi.nlm.nih.gov/16131969/ -
Systemic / extra-intestinal effects
Messaoudi M, et al. “Assessment of psychotropic-like properties of a probiotic formulation in rats and human volunteers.” Br J Nutr. 2011.
https://pubmed.ncbi.nlm.nih.gov/21838974/
These links lead to external research databases (PubMed). They are provided for information only and do not replace medical advice. Readers in Ireland should consult a GP, pharmacist, or other registered healthcare professional for personalised guidance.